Abstract
The COVID-19 outbreak, which emerged in late 2019, rapidly evolved into an unprecedented global public health crisis. An assessment of Ethiopia’s responses to the COVID-19 pandemic offers a unique learning experience for building stronger health systems and enhancing resilience against future health threats. This paper covers the major findings of a national study of the Government of Ethiopia’s COVID-19 response. The study followed a concurrent nested mixed methods design, combining quantitative and qualitative data collection at all levels of the health system. Primary data were collected from surveys of individuals involved in the COVID-19 pandemic response, health facility assessments, key informant interviews, and a review of COVID-19 response norms and standards. The study revealed that Ethiopia implemented a wide range of interventions across the WHO response pillars including multi-sectoral coordination and actions, partnerships with communities by engaging public figures, expanding molecular laboratory capacity, strengthening critical care facilities, and enhancing digitalization of health data. However, we detected a decline and a lack of institutionalization of COVID-19 practices, particularly in the areas of surveillance, laboratory testing, and case management. Our findings thus suggest that COVID-19 investments led to a strong response with robust implementation, but in the absence of a strong transition plan and limited capacity to apply the lessons learned, many of the COVID-19 response platforms were not effectively leveraged to strengthen the health system to address future responses.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the United States Agency for International Development (USAID). The funding supported the design, implementation, and analysis of the study. However, the content of this manuscript is solely the responsibility of the authors and does not necessarily reflect the views of USAID or the United States Government.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethiopian Public Health Institute Institutional Review Board approved the study (IRB number: EPHI-IRB-512-2023).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos